My question is for Dr. Fowler, who participated in the World Health Organization's solidarity clinical trial. Earlier, Dr. Gerdts said that the WHO set up an expert group so that we could strengthen our efforts to work together and share information. You said earlier that you had no conflict of interest in terms of research and grants.
Some people are concerned that intellectual property rights may impede access to treatments and vaccines. They're suggesting alternatives. I gathered from the response earlier that this is still ongoing. How should we manage intellectual property when it comes to the development of treatments and vaccines? In addition, could the traditional marketing contingencies affect the availability of a potential vaccine? Lastly, I want to know what you think about the possibility, which Dr. Gerdts touched on briefly earlier, of the public and private sectors working together on basic research.